Posts

Polycythemia Vera (PV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Polycythemia Vera (PV) Market Outlook Thelansis’s “Polycythemia Vera (PV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polycythemia Vera (PV) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Polycythemia Vera (PV) Overview Polycythemia vera (PV) is a chronic clonal myeloproliferative neoplasm defined by pathological erythrocytosis, driven in over 95% of cases by the JAK2 V617F somatic mutation — and rarely JAK2 exon 12 mutations — constitutively activating JAK-STAT signalling and causing unchecked red cell, and frequently white cell and platelet overproduction. Patients present with plethora, aquagenic pruritus, headache...
Post a Comment
Read more

Intermediate or High-Risk Myelofibrosis (MF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Intermediate or High-Risk Myelofibrosis (MF) Market Outlook Thelansis’s “Intermediate or High-Risk Myelofibrosis (MF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Intermediate or High-Risk Myelofibrosis (MF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Intermediate or High-Risk Myelofibrosis (MF) Overview Intermediate or high-risk myelofibrosis (MF) is a malignant myeloproliferative neoplasm characterised by clonal haematopoietic stem cell proliferation, progressive bone marrow fibrosis, extramedullary haematopoiesis, and cytopenias. Driver mutations in JAK2, CALR, or MPL constitutively activate JAK-STAT signalling, ...
Post a Comment
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Type 1 Diabetes Mellitus (T1D) Market Outlook Thelansis’s “Type 1 Diabetes Mellitus (T1D) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Type 1 Diabetes Mellitus (T1D) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Type 1 Diabetes Mellitus (T1D) Overview Type 1 diabetes mellitus (T1D) is a chronic autoimmune disorder driven by immune-mediated pancreatic beta-cell destruction, resulting in absolute insulin deficiency. Genetic susceptibility — particularly HLA-DR3/DR4 alleles — combined with environmental triggers initiates autoreactive T-cell infiltration; GAD65, IA-2, and ZnT8 autoantibodies serve as diagnostic and predi...
Post a Comment
Read more

Amyotrophic Lateral Sclerosis (ALS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Amyotrophic Lateral Sclerosis (ALS) Market Outlook Thelansis’s “Amyotrophic Lateral Sclerosis (ALS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Amyotrophic Lateral Sclerosis (ALS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Amyotrophic Lateral Sclerosis (ALS) Overview Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and invariably fatal neurodegenerative disease characterised by selective loss of both upper and lower motor neurons in the cortex, brainstem, and spinal cord, leading to progressive muscular paralysis and ultimately respiratory failure. The underlying pathophysiology is multifactorial ...
Post a Comment
Read more

Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Market Outlook Thelansis’s “Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Overview Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) is a genetic cardiac disorder, predominantly caused by autosomal dominant sarcomere protein mutations — most commonly in MYH7 and MYBPC3 — resulting in asymmetric left ventricular hypertrophy, myocyte d...
Post a Comment
Read more

Pancreatic Ductal Adenocarcinoma (PDAC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Pancreatic Ductal Adenocarcinoma (PDAC) Market Outlook Thelansis’s “Pancreatic Ductal Adenocarcinoma (PDAC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pancreatic Ductal Adenocarcinoma (PDAC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Pancreatic Ductal Adenocarcinoma (PDAC) Overview Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy arising from the exocrine epithelium of the pancreatic ducts, representing the vast majority of pancreatic cancers and carrying one of the poorest prognoses across all solid tumours. Its pathobiology is driven by a stepwise accumulation of somatic mutations — most crit...
Post a Comment
Read more

Acute Ischemic Stroke – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Acute Ischemic Stroke Market Outlook Thelansis’s “Acute Ischemic Stroke Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Ischemic Stroke treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Acute Ischemic Stroke Overview Acute ischemic stroke (AIS) is a time-critical neurological emergency resulting from sudden focal cerebral hypoperfusion, most commonly due to thrombotic occlusion of a cerebral artery or cardioembolic events — notably from atrial fibrillation — leading to irreversible infarction of brain tissue within a penumbra of potentially salvageable neurons. The underlying pathophysiology involves excitotoxicity, ox...
Post a Comment
Read more